AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase 3 Registrational Trial Seeks to Improve Survival Outcomes in Underserved HPV-negative R/M Head and Neck Cancer Patient PopulationTrial Launch Follows FDA Fast Track Designation of...
Source: marketscreener.com